| Name | ZLN 024 hydrochloride |
| Description | ZLN 024 hydrochloride is an AMPK allosteric activator and stimulates the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312). |
| In vitro | ZLN 024 hydrochloride increases the activity of α1β1γ1 by 1.5-fold and has an EC50 of 0.42 µM, and it increases the activity of α2β1γ1 by 1.7-fold with an EC50 of 0.95 µM. ZLN 024 hydrochloride also directly activates recombinant AMPK α1β2γ1, by 1.7-fold with an EC50 of 1.1 µM; and AMPK α2β2γ1, by 1.6-fold with an EC50 of 0.13 µM. ZLN 024 hydrochloride directly activates recombinant AMPK α1β1γ1 and its homolog α2β1γ1 in a concentration-dependent manner[1]. |
| In vivo | In C57BKS db/db mice, ZLN 024 hydrochloride(15 mg/kg/day; oral) improves glucose tolerance after 4 weeks of treatment. ZLN 024 hydrochloride reduces the fasting blood glucose by 15%. Liver tissue weight, triacylglycerol and the total cholesterol content a |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (124.42 mM), Sonication is recommended.
H2O : < 0.1 mg/mL (insoluble)
|
| Keywords | Inhibitor | AMP-activated protein kinase | ZLN-024 | ZLN 024 hydrochloride | inhibit | ZLN 024 Hydrochloride | ZLN-024 Hydrochloride | ZLN024 | ZLN 024 | ZLN024 Hydrochloride | AMPK |
| Inhibitors Related | Phenformin hydrochloride | AICAR | Doxorubicin hydrochloride | Adenosine monophosphate | Metformin | Methyl cinnamate | A-769662 | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 | AMPK activator 4 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Obesity Compound Library | Anti-Breast Cancer Compound Library | Antioxidant Compound Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | AMPK-Targeted Compound Library |
United States
